Name | Company | P/L % | MPV |
|
---|---|---|---|---|
Lord Glendonbrook |
![]() |
Stryker / NYQ:SYK | 442.90% | £380,028.83 |
Lord Glendonbrook |
![]() |
Abbott Laboratories / NYQ:ABT | 431.02% | £371,716.94 |
Lord Sassoon |
![]() |
Abbott Laboratories / NYQ:ABT | 307.81% | £285,468.06 |
Lord Grabiner |
![]() |
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
Baroness Noakes |
![]() |
Smith & Nephew / NYQ:SNN | 77.83% | £124,482.90 |
Lord Glendonbrook |
![]() |
Smith & Nephew / NYQ:SNN | 65.05% | £115,536.18 |
Lord Mance |
![]() |
Stryker / NYQ:SYK | 37.05% | £95,933.09 |
Lord Londesborough |
![]() |
Abbott Laboratories / NYQ:ABT | 23.30% | £86,306.74 |
Lord Howard of Rising |
![]() |
Ekf Diagnostics / LSE:EKF.L | 21.15% | £84,805.39 |
Lord Glendonbrook |
![]() |
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
Lord Browne of Madingley | Allurion / NYQ:ALUR | -35.95% | £44,833.83 | |
Lord Glendonbrook |
![]() |
Align Technology / NMS:ALGN | -52.72% | £33,098.81 |
Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |